# Anticancer Mechanisms

Mebendazole is a repurposed-drug candidate because it does not rely on one mechanism alone. It appears to interfere with several core cancer survival systems at once.

### Primary mechanisms

#### 1. Tubulin polymerisation inhibition

* disrupts microtubule formation
* arrests cell division
* acts through a classic anti-mitotic mechanism relevant to proliferating tumour cells

#### 2. Anti-angiogenic activity

* inhibits VEGFR2-related signalling
* reduces microvessel density in tumour models
* suppresses tumour blood-vessel formation

#### 3. Akt, NF-κB, and β-catenin pathway inhibition

* suppresses key survival and inflammatory signalling
* reduces metastatic and proliferative behaviour
* supports apoptosis and reduced resistance potential

#### 4. HIF suppression

* disrupts tumour hypoxia-response signalling
* relevant in aggressive and treatment-resistant tumour biology
* especially interesting in breast and hypoxia-driven models

#### 5. Apoptosis induction

* promotes programmed cell death in multiple cancer models
* can work alongside cell-cycle arrest and anti-angiogenic stress

#### 6. ERK / MAPK modulation

* inhibits ERK signalling in cancer cells
* may activate ERK-related immune signalling in immune cells, supporting anti-tumour responses
* this dual behaviour makes it mechanistically distinctive among repurposed and natural adjuncts

### TP53 context

Mebendazole appears less dependent on intact p53 than fenbendazole.

It has shown activity in **wild-type, mutant, and null** p53 settings.

Read the full breakdown in [Mebendazole and TP53](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/mebendazole-and-tp53.md).

We also have a section dedicated to learning about TP53.

There, you can explore how different drugs and natural compounds may be influenced by TP53 status, or may influence TP53-related biology.

Start with [TP53 in Cancer Overview](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/tp53-in-cancer-overview.md).

### Practical interpretation

This broad mechanism profile is one reason mebendazole remains one of the most compelling low-cost repurposing candidates in oncology.

### Key References

Mebendazole as a Candidate for Drug Repurposing in Oncology\
<https://pmc.ncbi.nlm.nih.gov/articles/PMC6769799/>

Mebendazole Exerts Anticancer Activity in Ovarian Cancer Cell Lines\
<https://pmc.ncbi.nlm.nih.gov/articles/PMC11763501/>

Repurposing of Mebendazole as an Anticancer Agent: A Review\
<https://rjptonline.org/HTMLPaper.aspx>

{% hint style="warning" %}
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
{% endhint %}

{% hint style="info" %}
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
{% endhint %}


---

# Agent Instructions: Querying This Documentation

If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.

Perform an HTTP GET request on the current page URL with the `ask` query parameter:

```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/off-label-drugs-for-cancer/mebendazole-in-oncology/anticancer-mechanisms.md?ask=<question>
```

The question should be specific, self-contained, and written in natural language.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.

Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.